论文部分内容阅读
Aim:To study the effects of Cortex Moutan medicinal combination in the nonalcoholic fatty liver insulin resistance rat.Methods:A rat model with nonalcoholic fatty liver insulin resistance was successfully established by receiving gavage with highfat emulsion once a day and freely feeding with 180g/L sucrose solution for 8 weeks which was based on the etiology of nonalcoholic fatty liver insulin resistance.Liver pathology observation was done to assess the fatty hepatic development during the modeling.Cortex Moutan medicinal combination was composed of Paeonol (Pae) and Total Glucosides of Cortex Moutan (TGM).Uniform Design was applied to screening the best compatibility which was evaluated by the level of TG in liver.Meanwhile weighted modification method was performed to find the best ratio of Pae and TGM.After the model was developed, the rats were administered the best compatibility of Cortex Moutan medicinal combination via gavage daily.Commercial analysis kits were used for the measurement, after the rats were sacrificed.Results:Rats developed abdominal obesity, insulin resistance and non-alcoholic fatty liver, which were markedly improved by the modeling.After weighted modification method was performed, we found that the best ratio of Pae and TGM is 3 to 1 and the effect on liver TG was remarkably improved compared with treated with Pae or TGM alone.After 4 weeks treatment with Cortex Moutan medicinal combination via gavage, the liver and serum levels of TC, TG, FFA significantly decreased.Conclusion:The improvement of prescription compatibility promotes the synergistic effect and improves the protective effect against liver TG.Cortex Moutan medicinal combination exerts protective effects against nonalcoholic fatty liver insulin resistance.